P/B
0,6
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
$123M
Market Cap • 9/25/2026
2020
(6 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
5,7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
7,2
EPS
—
Market Cap
Market Cap
123M
EV
-96,9M
EV/Revenue
-4,5
EV/EBITDA
0,7
EV/EBIT
0,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-100,5%
Total Yield
-100,5%
Payout
0%
Retained Earnings
-300,5M
Profitability
Gross Margin
91,7%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
17,7%
Capex/Revenue
2,4%
Capex/D&A
112,8%
Capex/OCF
-0,4%
SBC/OCF
—
% PPE
0,6%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
28,3%
CAGR Net Income 5Y
3,9%
CAGR EPS 5Y
-54,2%
CAGR OCF 5Y
30,9%
Leverage
N.D./EBITDA
1,6
Debt/Equity
0%
Current Ratio
13,6
Quick Ratio
12,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!